

SUPPLEMENTARY INFORMATION

Circulating Tumor DNA in a Breast Cancer Patient's Plasma Represents Driver Alterations in the Tumor Tissue

**Jieun Lee^{1,2§}, Sung-Min Cho^{3§}, Min Sung Kim⁴, Sug Hyung Lee^{4,5},
Yeun-Jun Chung^{3,6,7}, Seung-Hyun Jung^{5*}**

¹Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, Seoul 06591, Korea, ²Cancer Research Institute, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea, ³Integrated Research Center for Genome Polymorphism, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea, ⁴Department of Pathology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea, ⁵Cancer Evolution Research Center, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea, ⁶Department of Microbiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea, ⁷Precision Medicine Research Center, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea

Supplementary Table 2. A list of copy number alterations identified in a breast tumor by WES

Chromosome	Start	End	Event	Length	Cancer gene
chr1	127,420,311	249,250,621	Gain	121,830,311	<i>MDM4</i>
chr3	36,534,627	69,244,337	Loss	32,709,711	
chr4	164,087,858	191,154,276	Loss	27,066,419	
chr7	0	41,804,809	Gain	41,804,810	
chr7	51,258,647	59,900,000	Gain	8,641,354	<i>EGFR</i>
chr7	61,967,549	75,174,027	Gain	13,206,479	
chr7	75,174,027	151,884,364	Loss	76,710,338	
chr7	151,884,364	159,138,663	Gain	7,254,300	
chr8	0	33,371,138	Loss	33,371,139	
chr8	33,371,138	43,827,943	Amplification	10,456,806	<i>FGFR1</i>
chr8	45,600,000	146,364,022	Amplification	100,764,023	<i>MYC</i>
chr12	53,900,617	56,077,919	Gain	2,177,303	
chr12	57,592,078	80,603,169	Amplification	23,011,092	<i>CDK4, MDM2</i>
chr12	94,543,468	132,626,899	Loss	38,083,432	
chr12	132,626,899	133,851,895	Amplification	1,224,997	
chr14	67,389,335	107,349,540	Loss	39,960,206	
chr16	0	34,640,903	Gain	34,640,907	
chr17	0	24,000,000	Loss	24,000,001	<i>TP53</i>
chr19	0	19,770,314	Loss	19,770,315	<i>STK11</i>
chr20	0	25,734,258	Gain	25,734,259	
chr20	27,500,000	47,364,269	Gain	19,864,270	
chr20	47,364,269	57,415,391	Amplification	10,051,123	
chr20	57,415,391	63,025,520	Gain	5,610,130	

WES, whole-exome sequencing.